Broadcast Date: July 13, 2022
Time: 11:00 am PT, 2:00 pm ET, 20:00 CET
Adeno-associated viral vectors (AAV vectors) are essential tools for delivering gene therapy to patients and are usually manufactured using plasmid-based approaches. However, there are challenges with working with plasmids on a large scale, including consistency and scalability. In addition, manufacturing approaches must keep pace with the rapid scientific advances in the gene therapy field to meet the demands for high and consistent yields of AAV. Recently published data demonstrated that plasmid-free technology could produce over tenfold more AAV compared with a transient approach and particles which are 5- to 60-fold more infectious—which represents a scalable approach to AAV manufacturing.
In this GEN webinar, we will hear detailed information about the recent design of experiments studies to optimize a process for large-scale AAV manufacture using TESSA™ technology, scaling up to 50L with AAV6 and 200L with AAV2. AAV titer, quality, and infectivity stayed consistent at scale, demonstrating the robustness of our process for AAV manufacture.
A live Q&A will follow the presentation, offering you a chance to pose questions to our expert panelists.
Produced with support from: